US8110331092
US8110331092
Scribe Therapeutics Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 51.174.000 | 27.413.000 | 86.7% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 77.244.000 | 70.242.000 | 10.0% | |
| Operating Income | -26.070.000 | -42.829.000 | 39.1% |
| Pretax Income | -23.610.000 | -37.561.000 | 37.1% |
| Net Income Common Stockholders | -21.808.000 | -47.786.000 | 54.4% |
| -- | -- | -- | |
| -- | -- | -- |